Carbimazole differs from propylthiouracil in that:
A. It is dose to dose less potent
B. It has a shorter plasma half life
C. It does not produce an active metabolite
D. It does not inhibit peripheral conversion of
thyroxine to triiodothyronine
Show More Ask Question

1 Answer

Answer :

D. It does not inhibit peripheral conversion of
thyroxine to triiodothyronine
Like 0 like
Next Page →

Related

Description : 17.2 Triiodothyronine differs from thyroxine in that: A. It is more avidly bound to plasma proteins B. It has a shorter plasma half life C. It is less potent D. It has a longer latency of action (

Answer : B. It has a shorter plasma half life

Description : riiodothyronine differs from thyroxine in that: A. It is more avidly bound to plasma proteins B. It has a shorter plasma half life C. It is less potent D. It has a longer latency of action

Answer : B. It has a shorter plasma half life

Description : In the treatment of parkinsonism, bromocriptine differs from levodopa in the following respects except: A. It does not need conversion to an active metabolite B. It has a longer duration of ... with little/antagonistic action on D1 receptors D. It does not produce behavioral/psychiatric side effect

Answer : D. It does not produce behavioral/psychiatric side effects

Description : Enalapril differs from captopril in that: A. It blocks angiotensin II receptors B. It does not produce cough as a side effect C. It is less liable to cause abrupt first dose hypotension D. It has a shorter duration of action

Answer : C. It is less liable to cause abrupt first dose hypotension

Description : Methyldopa differs from clonidine in the following respect: A. It is less likely to cause rebound hypertension on sudden discontinuation B. It does not reduce plasma renin activity C. It has a central as well as peripheral site of antihypertensive action D. It does not produce central side effect

Answer : A. It is less likely to cause rebound hypertension on sudden discontinuation